Annovis Bio Reports Q3 2025 Financial Results with Reduced Net Loss

Annovis Bio, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $7.3 million, a decrease from a net loss of $12.6 million in the same period last year. For the nine months ending September 30, 2025, the company recorded a net loss of $19 million, slightly higher than the $18.7 million loss reported for the same period in 2024. The company's total operating expenses for the quarter were $7.4 million, up from $4.4 million in the prior year, primarily driven by increased research and development costs associated with ongoing clinical trials.

The company’s cash and cash equivalents increased to $15.3 million as of September 30, 2025, compared to $10.6 million at the end of 2024. This increase was attributed to successful financing activities, including a public offering that generated $19.3 million in net proceeds. Annovis Bio's total assets rose to $17.2 million, while total liabilities decreased to $4 million, down from $4.6 million at the end of 2024. The company’s accumulated deficit reached $153.9 million, reflecting its ongoing investment in research and development without generating revenue.

Annovis Bio has made significant strides in its clinical development pipeline, particularly with its lead product candidate, buntanetap, which targets neurodegenerative diseases such as Alzheimer’s and Parkinson’s. The company has completed several clinical trials, including a Phase 3 study in early Parkinson’s disease patients and a Phase 2/3 study in mild to moderate Alzheimer’s patients. The results from these studies have shown promise, with improvements in cognitive function and motor skills reported in trial participants. The company is currently preparing for regulatory submissions based on these findings.

In terms of operational metrics, Annovis Bio's research and development expenses for the third quarter of 2025 were $6.3 million, significantly higher than the $2.7 million reported in the same quarter of 2024. This increase reflects the costs associated with the ongoing clinical trials. The company’s general and administrative expenses decreased to $1.1 million from $1.7 million year-over-year, primarily due to reduced stock-based compensation and listing fees. The company’s employee headcount remains stable, supporting its ongoing clinical and administrative functions.

Looking ahead, Annovis Bio anticipates continued losses as it progresses through its clinical trials and seeks regulatory approvals for its product candidates. The company has indicated that it will need to raise additional capital to fund its operations and clinical development, as its current cash reserves are not sufficient to cover expenses for the next 12 months. Management is exploring various financing options, including public and private equity offerings, to secure the necessary funds for its ongoing projects.